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Expression and hypoxic regulation of the endothelin system in
endocrine cells of human and rat pancreatic islets
Abstract
CONTEXT: The success of pancreatic islet transplantation depends largely on the capacity of the islet
graft to survive the initial phase immediately after transplantation until revascularization is completed.
Endothelin-1 (ET-1) is a strong vasoconstrictor which has been involved in solid organ graft failure but
is also known to be a potent mitogenic/anti-apoptotic factor which could also potentially enhance the
survival of the transplanted islets. OBJECTIVE: Characterization of the endothelin system with regard
to a potential endothelin agonist/antagonist treatment. DESIGN: Regulated expression of the endothelin
system in human and rat pancreatic islets and beta-cell lines was assessed by means of
immunohistochemistry, competition binding studies, western blot, RT-PCR, real-time PCR and
transplant studies. RESULTS: ET-1, ETA- and ETB-receptor immunoreactivity was identified in the
endocrine cells of human and rat pancreatic islets. The corresponding mRNA was detectable in rat
beta-cell lines and isolated rat and human pancreatic islets. Competition binding studies on rat islets
revealed binding sites for both receptor types. ET-1 stimulated the phosphorylation of mitogen-activated
protein kinase, which was prevented by ETA- and ETB-receptor antagonists. After exposure to hypoxia
equal to post-transplant environment oxygen tension, mRNA levels of ET-1 and ETB-receptor of human
islets were robustly induced whereas ETA-receptor mRNA did not show significant changes.
Immunostaining signals for ET-1 and ETA-receptor of transplanted rat islets were markedly decreased
when compared to native pancreatic sections. CONCLUSIONS: In pancreatic islets, ET-1 and its
receptors are differentially expressed by hypoxia and after transplantation. Our results provide the
biological basis for the study of the potential use of endothelin agonists/antagonists to improve islet
transplantation outcome.
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ABSTRACT 
 
Context The success of pancreatic islet 
transplantation depends largely on the 
capacity of the islet graft to survive the initial 
phase immediately after transplantation until 
revascularization is completed. Endothelin-1 
(ET-1) is a strong vasoconstrictor which has 
been involved in solid organ graft failure but 
is also known to be a potent mitogenic/anti-
apoptotic factor which could also potentially 
enhance the survival of the transplanted islets. 
 
Objective Characterization of the endothelin 
system with regard to a potential endothelin 
agonist/antagonist treatment. 
 
Design Regulated expression of the 
endothelin system in human and rat 
pancreatic islets and beta-cell lines was 
assessed by means of immunohistochemistry, 
competition binding studies, western blot, 
RT-PCR, real-time PCR and transplant 
studies. 
 
Results ET-1, ETA- and ETB-receptor 
immunoreactivity was identified in the 
endocrine cells of human and rat pancreatic 
islets. The corresponding mRNA was 
detectable in rat beta-cell lines and isolated rat 
and human pancreatic islets. Competition 
binding studies on rat islets revealed binding 
sites for both receptor types. ET-1 stimulated 
the phosphorylation of mitogen-activated 
protein kinase, which was prevented by ETA- 
and ETB-receptor antagonists. After exposure 
to hypoxia equal to post-transplant 
environment oxygen tension, mRNA levels of 
ET-1 and ETB-receptor of human islets were 
robustly induced whereas ETA-receptor 
mRNA did not show significant changes. 
Immunostaining signals for ET-1 and ETA-
receptor of transplanted rat islets were 
markedly decreased when compared to native 
pancreatic sections. 
 
Conclusions In pancreatic islets, ET-1 and its 
receptors are differentially expressed by 
hypoxia and after transplantation. Our results 
provide the biological basis for the study of 
the potential use of endothelin agonists/ 
antagonists to improve islet transplantation 
outcome. 
 
 
INTRODUCTION 
 
The success of clinical islet transplantation 
for the cure of patients with type 1 diabetes 
mellitus is limited, despite the recent progress 
made with an improved islet isolation process 
or immunosuppressive regimen [1, 2, 3]. A 
widespread application of this attractive 
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alternative to standard insulin therapy or 
pancreas transplantation is limited by donor 
organ shortage and the requirement of 2-3 
donor pancreata per recipient to achieve 
insulin independence. A key factor for the 
need of such substantial amounts of donor 
tissue is early graft loss due to inadequate 
engraftment early after transplantation. It is 
suspected that 50-70% of the total 
transplanted islet mass is lost or non-
functional as a result of limited blood supply 
and subsequent hypoxia, the instant blood-
mediated inflammatory reaction (IBMIR), the 
energy status of the islets, the balance of pro- 
and anti-apoptotic mediators and graft 
rejection [4, 5, 6]. Transplanted islets are 
trapped in the distal branches of the portal 
system, resulting in local ischemia until 
neovascularization of the grafted islets has 
been completed [7]. 
Local ischemia may trigger the release of 
vasoactive mediators, of which endothelin-1 
(ET-1) and nitric oxide are the most potent in 
controlling hepatic blood flow. It has been 
demonstrated that an imbalance in hepatic 
vasoregulatory gene expression leads to 
microvascular dysfunction and therefore 
contributes to ischemia/reperfusion injury in 
organ transplantation [8, 9]. Among others, 
endothelins (ET-1, 2 or 3), a family of 21 
amino acid residue peptides, are the most 
potent vasoconstrictors known. ET exerts its 
biological activity by binding to different cell 
surface receptors, ETA or ETB. Both ET-
receptors belong to the G-protein-coupled 
receptor family which leads to the activation 
of diverse downstream kinases [10]. Besides 
vasoconstriction, ET mediation of several 
other biological activities has been detected, 
e.g. the production of cytokines, cell growth, 
cell adhesion and thrombosis, the release of 
nitric oxide and prostacyclin, the stimulation 
of insulin release and other functions [10, 11, 
12, 13, 14, 15]. ET-1 has also been described 
as exerting anti-apoptotic effects in the 
endothelium and cardiomyocytes [16, 17]. 
Selective ETA-receptor antagonists have been 
shown to mitigate hepatic ischemia/ 
reperfusion injury and to exert beneficial 
effects in experimental pancreas and liver 
transplantation by improving microcirculation 
and reducing tissue injury [18, 19]. Therefore, 
the use of selective ETA-receptor antagonists 
in islet transplantation could potentially 
improve hepatic microcirculation and 
counteract the near-ischemic conditions 
which are generated locally through the 
embolization of the portal branches by the 
islet graft. However, treatment with an 
endothelin receptor antagonist might affect 
islet cell biology directly, provided that 
endothelin receptors are also expressed in 
pancreatic islets. Depending on the receptor 
subtype expression on islet cells, endothelin 
may provoke either beneficial or detrimental 
biological effects which are independent of its 
vasoactive properties but crucial to the 
engraftment process [10]. Recent studies on 
the expression of endothelin and its receptors 
in pancreatic islets are incomplete and 
inconclusive [20, 21]. In order to evaluate 
potential therapeutic strategies in islet 
transplantation, it is essential to obtain a 
better understanding of the endothelin system 
in the endocrine cells of pancreatic islets. The 
present study focuses on the precise 
localization of ET-1 and the two main 
receptors, ETA and ETB, in endocrine cells of 
human and rat pancreatic islets and in islets 
transplanted into the liver of syngeneic rats. 
Binding studies with radiolabeled ET-1 and 
non-labeled competitors specific for either 
receptor were performed to elucidate the 
expression of ETA- and ETB-receptors. We 
also studied the functionality of endothelin 
receptors in isolated rat islets by their ability 
to induce phosphorylation of p42/44 mitogen-
activated protein (MAP) kinase upon 
stimulation with ET-1. Quantitative 
polymerase chain reaction (PCR) was 
performed to study the regulation of 
endothelin and its receptors under hypoxic 
conditions at an oxygen tension (1% O2) 
comparable to the transplant site in the liver 
[22]. Our results demonstrate the presence of 
a functional and hypoxically regulated 
endothelin system in the endocrine cells of 
pancreatic islets which suggests a biological 
role other than the regulation of endothelial 
function. 
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SUBJECTS, MATERIALS AND 
METHODS 
 
LiberaseTM and DNAse were obtained from 
Roche Molecular Biochemicals (Basel, 
Switzerland). Cell culture media, Hanks’ 
balanced salt solution (HBSS), Roswell Park 
Memorial Institute 1640 (RPMI 1640), 
Connaught Medical Research Laboratories 
1066 (CMRL 1066), GlutaMax, sodium 
pyruvate, antibiotic-antimycotic solution were 
all obtained from Life Technologies, Gibco 
BRL (now: Invitrogen AG, Basel, 
Switzerland). ETA-receptor antagonist 
(BQ123), ETB-receptor antagonist (BQ788), 
and ETB-receptor agonist (IRL1620) were 
purchased from Calbiochem (Juro Supply, 
Switzerland). 
 
Cell Lines and Culture Conditions 
 
Rat beta-cell lines INS-1 (kindly provided by 
C. Wollheim, Geneva, Switzerland) and 
RINm5f (American Type Culture Collection, 
Manassas, VA, USA) were cultured in RPMI 
1640 supplemented with 1 mM sodium 
pyruvate, 10% fetal calf serum (FCS) (PAA, 
Vienna, Austria), 1 mM GlutaMax and 
antibiotic-antimycotic solution (100 U/mL 
penicillin G sodium, 100 U/mL streptomycin 
sulfate and 0.25 µg/mL amphotericin B as 
fungizone in 0.85% saline) and 50 µM beta-
mercaptoethanol. The cells were incubated in 
a humidified incubator at 37°C, 5% CO2/95% 
air. 
 
Isolation o Rat Islets 
 
Male Sprague-Dawley or Lewis rats (225-275 
g from Harlan Netherlands B.V., Horst, The 
Netherlands) were anaesthetized with 
Isoflurane (Baxter A.G., Volketswil, 
Switzerland) and subsequently sacrificed by 
neck dislocation. Islet isolation and 
purification were performed according to a 
modified procedure described earlier [23]. In 
brief, after cannulation of the common bile 
duct, a 10 mL enzyme solution (LiberaseTM 
0.17-0.33 mg/mL and DNAse 0.1 mg/mL in 
HBSS) was instilled for retrograde perfusion 
of the pancreas. After organ procurement, 
enzymatic digestion took place for 15-30 
minutes at 37°C in a shaking water bath. 
Following a wash step in HBSS with 10% 
FCS and filtration through cheese cloth, islets 
were obtained by centrifugation in a 
discontinuous density gradient of Histopaque-
1077 (Sigma Diagnostics Inc., St. Louis, MO, 
USA) and HBSS with subsequent hand-
picking. Islet purity was generally greater 
than 95%. Isolated rat islets were cultured in 
RPMI 1640 as described in Cell Lines and 
Culture Conditions in a humidified incubator 
at 37°C, 5% CO2/95% air, unless specified 
otherwise. For transplantation purposes, 
isolated Lewis islets were cultured overnight, 
then washed three times with 10 mL of HBSS 
and 2% Lewis rat serum and resuspended in 
washing buffer and placed on ice until 
transplantation. Experiments under hypoxic 
conditions (0.8-1.2% O2) were performed in a 
hypoxic chamber with an intermediate 
floodgate system for the hermetic transport of 
dishes (Coy Laboratory Products, Grass Lake, 
MI, USA). 
 
Rat Islet Transplantation 
 
Inbred male Lewis rats (150-175 g) were 
treated with a single injection of 
streptozotocin (75 mg/kg i.p.). Only rats with 
non-fasting blood glucose of more than 15 
mM for 3 consecutive days were considered 
diabetic. The rats were anesthetized by 
sevoflurane inhalation and the abdominal 
cavity was accessed by midline incision. The 
portal branches to the left, middle and right 
liver lobes were temporarily closed with 
microvascular clamps, after which 400-450 
islets in a volume of 150 μL HBSS were 
injected into the portal vein by a 26-gauge 
needle, directing the islets to the caudate liver 
lobes. The clamps were released and the 
injection needle was removed. Bleeding was 
stopped with a cotton swap by gentle 
compression at the site of injection. After 
closing the abdomen with sutures, the 
recipient was allowed to recover. The caudate 
liver lobes were harvested under sevoflurane 
anesthesia 24 h after transplantation. 
 
Isolation o Human Islets 
 
Human islets were isolated from cadaveric 
pancreata of heart-beating donors at the 
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Division of Endocrinology and Diabetes, 
University Hospital of Zurich, according to 
the method described previously [24]. 
Informed consent for organ donation was 
asked for and obtained by the donors’ 
relatives. The 13 donors (7 females; 6 males) 
had no previous history of diabetes or 
metabolic disorders. Their median age was 59 
years (range: 40-71 years) and the median 
body mass index was 25.3 kg/m2 (range: 19.6-
31.5 kg/m2). Cold ischemia time until 
perfusion of pancreatic duct with LiberaseTM 
solution averaged 5.5±2.1 h (range: 2.0-9.2 
h). Isolated human islets were cultured in 
CMRL 1066 as described in Cell Lines and 
Culture Conditions for 16-24 h before 
exposure to hypoxic culture conditions as 
described above. 
 
Immunofluorescent Stainings 
 
Tissue specimens (human pancreatic biopsies, 
rat pancreata and livers) were fixed in 
formalin solution for 24 h, embedded in 
paraffin and cut into 5 μm sections. After 
deparaffinization, the slides were placed in 10 
mM citrate buffer (pH 6.0) and heated in a 
microwave oven for 10 minutes (600 W) for 
antigen retrieval. The blocking of unspecific 
binding was performed in 10% normal 
donkey serum in PBS for 30 min. Sections 
were incubated overnight at 4°C with 
following primary antibodies: Guinea pig 
anti-insulin (A0564), dilution 1:100; rabbit 
anti-glucagon (A0565), dilution 1:100; rabbit 
anti-somatostatin (A0566), dilution 1:300 (all 
from DAKO Cytomation, Glostrup, 
Denmark). Mouse anti-ET-1 (803-001-R100), 
dilution 1:100; sheep anti-ETA-receptor (210-
507-C250), dilution 1:50; sheep anti-ETB-
receptor (210-506-C250), dilution 1:50 (all 
from Alexis Corporation, Lausen, 
Switzerland); rabbit anti-ETA-receptor (AER-
001), dilution 1:100; rabbit anti-ETB-receptor 
(AER-002, both Alomone Labs, Jerusalem, 
Israel), dilution 1:100. For detection, the 
following secondary antibodies were used: 
fluorescein-5-isothiocyanate- (FITC)-
conjugated rabbit anti-guinea pig IgG (F0233, 
DAKO Cytomation, Glostrup, Denmark), 
dilution 1:20; Cy2TM-conjugated donkey anti-
rabbit IgG (711-225-152), dilution 1:100; 
Cy3TM-conjugated donkey anti-mouse IgG 
(715-165-150); rhodamine-conjugated donkey 
anti-sheep IgG (713-295-147), dilution 1:100; 
Cy3TM-conjugated donkey anti-rabbit IgG 
(711-165-152), dilution 1:100 (all from 
Jackson Immuno Research Laboratories, West 
Grove, PA, USA). Binding of ET-1 antibody 
in the immunoneutralization assay was made 
visible using the biotin-streptavidin-based 
Histostain® broad-spectrum kit (Zymed, San 
Francisco, CA, USA) according to the 
manufacturer’s protocol. Slides were mounted 
in HydromountTM (National Diagnostics, 
Atlanta, GA, USA) and studied with a Zeiss 
Axioplan® 2 imaging microscope coupled to 
Axiocam® digital camera and AxioVision® 
software (version 2.0.5; Zeiss, Feldbach, 
Switzerland). 
 
Antibody Immunoneutralization 
 
To assess the specificity of ET-1, ETA-, and 
ETB-receptor immunostaining, antibodies 
were preabsorbed with the corresponding 
peptide for 2 h at 37°C with a 1,000-fold 
molar excess of either recombinant ET-1 
(155-001-PC01, Alexis Corporation, Lausen, 
Switzerland) or the specific peptides for ETA- 
and ETB-receptor provided by the supplier 
(Alomone Labs, JerUSAlem, Israel). 
 
RT-PCR 
 
Total RNA isolation from cells (INS-1, 
RINm5f) or purified rat or human islets was 
performed using TriZol reagent (Invitrogen 
AG, Basel, Switzerland) according to the 
manufacturer’s guidelines. After RNA 
isolation, reverse transcription was carried out 
with the Super Script first strand synthesis 
system (11904-018, Invitrogen AG, Basel, 
Switzerland) and oligo dT priming. 
Subsequent PCR amplification was performed 
with 30-40 cycles of 30 sec at 94°C, 30 sec at 
54-60°C and 1 min at 72°C (Taq DNA 
Polymerase 18038-042, Invitrogen AG, Basel, 
Switzerland). PCR products were separated 
on 1% agarose gel, and pictures were taken 
with a gel documentation system 
(AlphaImager, Alpha Innotech, San Leandro, 
CA, USA). Amplification of human beta-actin 
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served as internal standard and expression 
levels were shown to be unaffected by the 
experimental conditions. All primers were 
designed to be intron-spanning. Primer 
sequences, PCR fragment length, and 
amplification conditions of rat ET-1, ETA-, 
ETB-receptor and proinsulin were as follows. 
ET-1: 5’-atcatctgggtcaacactc-3’ (sense), 5’-
gaatctcctggctctctg-3’ (antisense), 727 bp 
(annealing: 50°C; 30 cycles). ETA-receptor: 
5’-ttcgtcatggtacccttcga-3’ (sense), 5’-
gatactcgttccattcatgg-3’ (antisense), 546 bp 
(annealing: 57°C; 40 cycles). ETB-receptor: 
5’-ttcacctcagcaggattctg-3’ (sense), 5’-
aggtgtggaaagttagaacg-3’ (antisense), 474 bp 
(annealing: 57°C; 40 cycles). Proinsulin: 5’-
acaatcatagaccatcagcaagc-3’ (sense), 5’-
cagttggtagagggagcaga-3’ (antisense), 354 bp 
(annealing: 55°C; 30 cycles). Primers 
sequences, PCR fragment length, and 
amplification conditions of human ET-1, 
ETA-receptor, ETB-receptor and beta-actin 
were as follows. ET-1: 5’-ttctctctgctgtttgtggctt-3’ 
(sense), 5’-ccagcacttcttgtctttttgg-3’ (antisense), 
338 bp (annealing: 50°C; 27 cycles). ETA-
receptor: 5’-acttcagctttcaaatacattaaca-3’ (sense), 
5’-ctgcttaagatgttcagtgagggc-3’ (antisense), 
674 bp (annealing: 50°C; 29 cycles). ETB-
receptor: 5’-ttccaacgccagtctggcgcggtc-3’ (sense), 
5’-gtcaatactcagagcacatagact-3’ (antisense), 
423 bp (annealing: 50°C; 30 cycles). Beta-
actin: 5’-gatgacccagatcatgtttg-3’ (sense), 5’-
gagcaatgatcttgatcttc-3’ (antisense), 641 bp 
(annealing: 50°C; 20 cycles). 
 
Quantitative RT-PCR 
 
Human islet RNA isolation procedure and 
first strand synthesis was performed as 
described above. Primers were designed with 
respect to exon/exon boundaries using Primer 
Express® version 2.0 (Applied Biosystems, 
Foster City, CA, USA). Sequence-specific 
fluorescent TaqManTM probes were designed 
for each target. Primer sequences, probe 
sequence and PCR fragment length, of human 
ET-1, ETA-receptor, ETB-receptor and beta-
actin were as follows. ET-1: 5’-
gctcgtccctgatggataaag-3’ (sense), 5’-
agggcttccaagtccatacg-3’ (antisense), 5’-
tgtgtctacttctgccacctggacatca-3’ (probe), 101 
bp. ETA-receptor: 5’-gggatcaccgtcctcaacct-3’ 
(sense), 5’-cacgactccaggaggcaact-3’ (antisense), 
5’-ctctgtacctgtcaacactaaga-3’ (probe), 70 bp. 
ETB-receptor: 5’-ggttccaaaatggacagcag-3’ 
(sense), 5’-caccaatcttttgctgtcttg-3’ (antisense), 
5’-acagccagaaccacagagaccaccc-3’ (probe), 
189 bp. Beta-actin: 5’-tcgcctttgccgatcc-3’ 
(sense), 5’-cgaagccggccttgc-3’ (antisense), 5’-
tcgacaacggctccggcatg-3’ (probe), 111 bp. 
Sequence detection of target genes was 
performed in an ABI Prism 7000 system 
(Applied Biosystems, Foster City, CA, USA) 
according to the manufacturer’s guidelines. 
The amplification parameters were 50°C for 2 
min, 95°C for 10 min and 40 cycles of 95°C 
for 15 sec and 60°C for 1 min. Fluorescence 
emission from individual PCR tubes and 
cycle of threshold (Ct) values were collected 
corresponding to the PCR cycle number at 
which the fluorescence was detectable above 
an arbitrary threshold, based on baseline data 
within cycles 3 to 15. The arbitrary threshold 
was chosen to ensure that the Ct values were 
obtained within the exponential phase of 
PCR. To normalize the differences in the 
amount of total RNA added to the reaction, 
amplification of the housekeeping gene beta-
actin was performed as an endogenous 
control. Samples were run in triplicates and 
differences were calculated as 2-((∆CtHypoxia) - 
(∆CtNormoxia)) whereas ∆Ct represents the 
differences of Ct-values of the transcript of 
interest and the endogenous control beta-actin 
at the respective experimental conditions. No 
error bars can be computed for the 24 h 
normoxic reference point (calibrator) due to 
the delta-delta ct real-time analysis method of 
always setting the calibrator to a value of 1. 
 
Receptor Binding Assays 
 
Isolated rat islets were dispersed into single 
cell suspension by mild trypsinization 
(0.005% trypsin dissolved in PBS with 0.05 
mM EDTA) and subsequent mechanical 
dissociation by pipetting through a Pasteur 
pipette. Islet cells were taken up in HBSS and 
0.3% bovine serum albumin (BSA) and 
incubated in the presence of 200 pM 125I-ET-1 
(IM223, Amersham, Buckinghamshire, 
United Kingdom) for 2 h at 37°C. the excess 
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of unlabeled ET-1 (1 µM; 155-001-PC01, 
Alexis Corporation, Lausen, Switzerland) was 
used to measure unspecific binding, and total 
binding was assessed in the absence of 
unlabeled ET-1. Bound ligand was separated 
from unbound by centrifugation through 
mineral oil, after which the cell pellet was 
measured for radioactivity. Specific binding 
to ETA- or ETB-receptor was determined by 
competition binding with ETB- receptor 
agonist (IRL1620, 1 µM), ETB- receptor 
antagonist (BQ788, 1 µM) or ETA-receptor 
antagonist (BQ123, 1 µM), respectively.  
 
Phosphorylation of p42/p44 MAP Kinase 
 
Rat islets were isolated and incubated 
overnight for recovery. The islets were then 
washed in PBS and resuspended in RPMI 
1640 supplemented with 0.5% FCS, 1 mM 
GlutaMax and antibiotic-antimycotic solution 
(100 U/mL penicillin, 100 U/mL 
streptomycin sulfate and 0.25 µg/mL 
amphotericin B as fungizone in 0.85% saline). 
Aliquots of 150-200 islets were incubated in 
the presence of ETA- (BQ123; 2.2 µM) and/or 
ETB- receptor antagonist (BQ788; 0,12 µM) 2 
h prior to stimulation with ET-1 (0.01-1 µM). 
Ten minutes after the addition of ET-1, the 
islets were immediately lysed in ice cold 50 
mM HEPES, pH 7.4, 1% Triton X-100, 4 mM 
EDTA, 1 mM NaF, 0.1 mM Na3VO4, 1 mM 
Na4P2O7; and 1% protease inhibitor cocktail 
(P8340, Sigma Diagnostics Inc., St. Louis, 
MO, USA) and protein concentration was 
determined. 
 
Western Blot 
 
Equal amounts of protein (20-50 µg) were 
separated by 10% or 15% SDS-PAGE and 
transferred onto a nitrocellulose membrane 
(BioRad, Hercules, CA, USA). The 
membrane was incubated overnight at 4°C 
with either anti-phospho-p42/p44 MAP 
kinase antibody (9101) or anti-p42/p44 MAP 
kinase antibody (9102; both from Cell 
Signaling Technology Inc., Danvers, MA, 
USA) diluted 1:1,000 in 2% fat free milk 
diluent (KPL, Gaithersburg, MD, USA) in 
TBS/0.1% Tween-20. This was followed by 
incubation with horseradish peroxidase-
conjugated secondary antibody (goat anti-
rabbit IgG 1:10,000; 170-6515 BioRad, 
Hercules, CA, USA) for 1 h at room 
temperature. Signals were visualized by 
chemiluminescent detection with an enhanced 
chemiluminescent reagent (ECL, Amersham, 
Buckinghamshire, United Kingdom) 
according to the manufacturer’s protocol and 
exposed to imaging film (Hyperfilm ECL, 
Amersham, Buckinghamshire, United 
Kingdom). Band intensities were analyzed by 
densitometry (AlphaImagerTM, Alpha 
Innotech Corporation, San Leandro, CA, 
USA). Phospho-p42/p44 MAP kinase signals 
were normalized for total p42/p44 MAP 
kinase.  
ETHICS  
Rat islets  
All procedures and experimental protocols 
were performed in accordance with Swiss 
animal protection laws.  
Human islets  
Informed consent for organ donation was 
asked for and obtained from the donors’ 
relatives. All studies performed were in 
accordance with Swiss laws and medical 
guidelines.  
STATISTICS  
The results are given as mean and standard 
deviation (±SD) or median, interquartile, and 
range. Statistical comparison between the 
control and the treatment groups was carried 
out using one-way ANOVA. Dunnett’s two-
tailed multiple comparison test was applied 
when more than one group was compared 
with the control/reference group. The 
software used was GraphPad Prism 4.00 
(GraphPad Software Inc., San Diego, CA, 
USA). Two-tailed P values of less than 0.05 
were considered statistically significant.  
RESULTS 
 
Immunohistochemical Studies of the 
Endothelin System on Rat and Human 
Islets  
To determine the presence of ET-1 and its 
receptors ETA and ETB on human and rat 
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Figure 1. Expression of endothelin-1 (ET-1) and its corresponding receptors ETA and ETB in comparison to islet-
specific hormones in human and rat pancreatic sections. Positive staining for components of the endothelin system are 
shown in red whereas islet specific hormones are visualized in green. The yellow color in the merged pictures (A3-M3)
represents the co-expression of indicated antigens within individual cells. Arrows designate identical cells within the 
corresponding column. Rat sections are only shown where immunofluorescence staining differs from human sections. 
L3, arrow head: positive immunostaining of ETB-receptor in vascular endothelium. Bars = 50 µm. 
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pancreatic islets, co-staining studies with 
islet-specific hormones were performed on 
whole pancreatic sections. In human 
pancreatic beta-cells, all three components of 
the endothelin system (ET-1, ETA- and ETB-
receptor) were detected whereas alpha-cells 
were only positive for ET-1 (Figure 1). 
Somatostatin-expressing delta-cells were 
negative for all three components. 
Interestingly, co-staining patterns differed in 
the two species. As opposed to human 
pancreatic islets, the alpha-cells of rat islets 
were also positive for ETB-receptor and 
weakly positive for ETA-receptor while delta-
cells showed immunoreactivity for ET-1 (not 
shown). Figure 2 summarizes the differences 
in species-specific co-expression patterns of 
endothelin and its receptors with islet-specific 
hormones. In order to confirm the specificities 
of the antibodies, competition immunoassays 
were performed (Figure 3). ET-1 and ETB-
receptor immunoreactivity was no longer 
detectable after preabsorption of the antibody 
with a 1,000-fold molar excess of the 
corresponding peptide. Since competition 
with the ETA-receptor specific peptide was 
unsatisfactory, an unspecific staining by this 
antibody could not be excluded. However, 
both ETA-receptor antibodies derived from 
different suppliers were consistent in terms of 
their staining pattern in pancreatic islets. 
 
Figure 2. Competition assay: specificity of antibodies used. Preabsorption of ET-1 and ETB-receptor antibody with a 
1,000-fold molar excess of the corresponding peptide confirms the specificity of the respective antibodies. Competition 
with the ETA-receptor-specific peptide was unsatisfactory; an unspecific staining by this antibody cannot be excluded. 
However, both ETA-receptor antibodies derived from different suppliers were consistent in terms of their staining
pattern in pancreatic islets. Bar = 50 µm; same magnification in all pictures.
Figure 3. Overview of the localization of the 
endothelin system in comparison to islet-specific 
hormones. Co-localization is indicated by a check 
mark (9: positive; (9): weakly positive), no co-
localization by a cross (8: negative). Species-specific 
differences in co-localization are emphasized by grey 
boxes. 
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ET-1 Binding Studies on Isolated Rat Islets 
 
To demonstrate that ETA- and ETB-receptor 
immunoreactivity represents the expression of 
ligand binding endothelin receptors, ET-1 
binding assays were performed with dispersed 
rat islet cells. Maximal specific binding of 
radiolabeled ET-1 was 52.2±11.6 fmol/mg 
protein with an IC50 value of 0.37 nM, 
indicating the presence of high-affinity 
binding sites (Figure 4a). Maximal inhibition 
of radioligand binding by an excess of the 
specific ETA-receptor antagonist BQ123 
(51±21%, n=3) was comparable to those of 
the specific ETB-receptor agonist IRL1620 
(45±22%, n=3; P=0.742) and ETB-receptor 
antagonist BQ788 (62±11%, n=3; P=0.346) 
(Figure 4b). The inhibitory capacity of these 
ligands in the range of 40-60% suggests that 
pancreatic islets express both ETA- and ETB-
receptors in the ratio of roughly 1:1. Ligand 
binding in the presence of both antagonists 
(BQ123/BQ788; 22±13%, n=3; P=0.173 vs. 
BQ123) could not be inhibited completely 
which might indicate the presence of a third 
type of endothelin-binding receptor. 
 
ET-1 Stimulates Phosphorylation of 
p42/p44 MAP kinase in Isolated Rat Islets 
 
ET-1 has been shown to activate p42 and p44 
MAP kinases through a protein kinase C 
(PKC)-dependent pathway [25]. To test 
whether the ligand binding capacity in 
pancreatic islet cells also translates into 
activation of an ET-1 relevant signaling 
pathway, phosphorylation of MAP kinases 
upon stimulation with ET-1 was analyzed. 
While phorbol 12-myristate-13-acetate 
(PMA), another known activator of MAP 
kinase, stimulated phosphorylation of p42/p44 
by more than 4-fold, the maximal response to 
treatment with ET-1 was at the most 2.5-fold 
(Figure 5). The relatively small response of 
ET-1 on p42/p44 phosphorylation may 
originate from relatively high basal MAP 
kinase activity in freshly isolated rat islets. 
This observation is consistent with a previous 
Figure 5. ET-1 induces phosphorylation of p42/p44 
MAP-kinase in rat islet cells through the activation of 
ETA- and ETB-receptors. Rat islets were stimulated 
either with phorbol 12-myristate-13-acetate (PMA) or 
ET-1 for 10 min and phosphorylation of p42/44 
mitogen-activated protein kinase was determined by 
Western Blot. Pre-incubation with ETA-receptor 
antagonist (BQ123) or ETB-receptor antagonist 
(BQ788), either alone or in combination, reduces 
phosphorylation of p42/44 MAP kinase by ET-1. 
Reprobing with antibody directed against total p42/44 
MAP kinase serves as a loading control. One out of 
three similar experiments is shown. 
Figure 4. ET-1 binds to high affinity binding sites on 
dispersed rat islet cells. a. The cells were incubated for 
2 h with 125I-ET-1 (200 pM), and increasing 
concentrations of unlabeled ET-1. Measurements were 
carried out in triplicate, three experiments were 
performed. b. Competition binding of 125I-ET-1 (200 
pM) in the presence of 10 µM ETA-receptor antagonist 
BQ123, ETB-receptor antagonist BQ788 or ETB-
receptor agonist IRL1620. Data are mean±SD from 
three independent experiments. 
JOP. J Pancreas (Online) 2008; 9(2):133-149. 
JOP. Journal of the Pancreas - http://www.joplink.net - Vol. 9, No. 2 - March 2008. [ISSN 1590-8577] 142
report, describing sustained activation of 
MAP kinase during the first 24 h after the 
isolation procedure [26]. However, pre-
incubation with the selective ETA or ETB-
receptor antagonist (BQ123 or BQ788) 
blocked the ability of ET-1 to induce 
phosphorylation of MAP kinase p42/p44 
completely. When combined, BQ123 and 
BQ788 reduced the activation of MAP kinase 
even below the basal value of untreated 
control islets (43±4%, n=3 vs. 100%; 
P<0.001). This suggests that ET-1 expressed 
in pancreatic islets may act in an autocrine 
fashion and stimulate MAP kinase activation. 
Thus, the results strongly indicate that, in 
isolated rat islets, both ETA- and ETB-
receptors are expressed and are biologically 
active. 
 
mRNA of Endothelin and Its Receptors in 
Beta-cell Lines and Isolated Rat Islets 
 
To substantiate our immunohistological 
observations that all three components of the 
endothelin system are expressed in pancreatic 
beta-cells, we aimed to demonstrate the 
presence of ET-1, ETA- and ETB receptor 
mRNA in rat beta-cell lines by means of a 
reverse transcriptase polymerase chain 
reaction (RT-PCR). For all the PCR reactions, 
intron-spanning primer pairs were chosen to 
exclude the amplification of genomic DNA. 
DNA-fragments of ET-1, ETA-receptor and 
ETB-receptor from both INS-1 and RINm5f 
cells could be amplified, though at quite 
different intensities (Figure 6). Even though 
no quantitative assessment was performed, 
mRNA expression levels from rat islets were 
comparable to RINm5f cells, but clearly 
stronger when compared to the levels 
obtained from INS-1 cells. Different mRNA 
expression levels of the components of the 
endothelin system may simply reflect the 
property of the particular beta-cell line. On 
the other hand, it is conceivable that intraislet 
endothelium also contributes to the signals 
generated by RT-PCR. 
Islet transplantation is inherently correlated to 
prolonged periods of ischemia as a 
consequence of the transient avascular state of 
the grafted tissue. It has previously been 
demonstrated that partial oxygen tension in 
the transplant site in the liver may be as low 
as 1% O2 as compared to 5-6% O2 in the 
native pancreas [22]. Therefore regulation of 
ET-1, ETA- and ETB-receptor transcript levels 
in purified isolated human islets after 
exposure to hypoxia (1% O2) was investigated 
by means of semi-quantitative and 
quantitative (real-time) RT-PCR (Figures 7 
Figure 7. Semi-quantitative assessment of hypoxic 
regulation of ET-1, ETA-, and ETB-receptor mRNA 
transcript levels in human isolated islets. RNA from 
isolated human islets incubated at either normoxic 
(21% O2) or hypoxic (1% O2) culture conditions for 24 
and 48 h was reversed transcribed and amplified with 
specific intron-spanning primers for either ET-1, ETA-, 
or ETB-receptor. PCR cycle numbers were chosen to 
guarantee linear amplification. Amplification of the 
housekeeping gene beta-actin served for normalization. 
Figure 6. ET-1, ETA-, and ETB-receptor mRNA are 
expressed in rat islets and rat beta-cell lines. RT-PCR 
from isolated total RNA from freshly isolated rat islets 
and rat beta-cell lines (INS-1, RINm5f) was performed 
with intron-spanning primers specific for ET-1 (727
bp), ETA- (546 bp), ETB-receptor (474 bp) and 
proinsulin (354 bp). For reference, a 100 bp-ladder 
DNA size marker is shown (arrow: 600 bp). 
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and 8). Hypoxic ET-1 expression levels were 
increased by 2.3-fold after 24 h (P<0.05) and 
4.7-fold after 48 h (P<0.001) (average values; 
Figure 8). ETB-receptor mRNA levels were 
increased by 3.3 fold (P<0.01) after 48 h of 
hypoxia as compared to normoxia. There was 
a tendency towards upregulation after 24 h of 
hypoxia which did not reach statistical 
significance. In contrast to ET-1 and ETB-
receptor, transcript levels of ETA-receptor did 
not show significant changes upon hypoxic 
exposure. 
These data indicate that hypoxia induces the 
expression of ET-1 and ETB-receptor 
transcript levels whereas ETA-receptor 
transcription levels are slightly reduced. 
 
Immunohistochemical Studies of the 
Endothelin System in Rat Islets Before and 
After Transplantation 
 
To investigate whether hypoxic regulation of 
the endothelin system also occurs in vivo, we 
performed immunohistochemical staining of 
ET-1 and its receptors (ETA and ETB) in islet 
grafts one day after intrahepatic (lobus 
caudatus) transplantation into syngeneic 
normoglycemic rats. At this stage, islets have 
been assumed to experience hypoxic 
conditions due to their avascular state. Similar 
to our in vitro data of hypoxic islets and 
compared to pancreatic sections, ETB-receptor 
expression in transplanted islets appeared to 
be increased while ETA-receptor 
immunoreactivity was completely lost (Figure 
9). Immunostaining for ET-1 was no longer 
detectable which is discordant with the 
hypoxic upregulation of rat islet ET-1 
transcript levels in vitro and could be 
attributed to transplant site 
microenvironmental factors other than 
hypoxia. 
 
DISCUSSION 
 
Endothelins have been shown to be involved 
in the physiology and pathophysiology of the 
vascular system, heart, lungs, kidney, brain, 
liver and various other tissues [10]. 
Endothelins mediate diverse biological effects 
in an autocrine or paracrine fashion which can 
either be beneficial or detrimental. With 
Figure 8. Quantitative RT-PCR analysis of ET-1, ETA-,
or ETB-receptor mRNA levels in human islets 
incubated for 24 h and 48 h at normoxic (21% O2) or 
hypoxic (1% O2) conditions. Results are box 
(interquartile range; median value is shown within the 
box) and whisker (minimal and maximal values) plots
from 11 human islet isolations. No variability can be 
computed for the 24 h normoxic reference point 
(calibrator) due to the delta-delta ct real-time analysis 
method of always setting the calibrator to a value of 1.
P values resulted from the comparison of 24 and 48 h 
hypoxia vs. 24 h normoxic conditions 
Number of observations: 24 h normoxia (n=11); 24 h 
hypoxia (n=11); 48 h normoxia (n=8); 48 h hypoxia (n=8)
*P<0.05; **P<0.01, ***P<0.001 
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regard to intrahepatic islet transplantation, 
pre- and/or post-operative treatment with 
endothelin receptor antagonists would 
potentially improve graft perfusion and 
function, similar to the beneficial effects 
described in an experimental model involving 
transplantation of a pig pancreas or hepatic 
ischemia/reperfusion in rats [19, 27]. 
However, this treatment could also affect the 
islet graft in a negative fashion due to the 
blockade of the antiapoptotic effects of the 
endothelin system [16, 17]. The present study 
was performed to determine whether the 
endothelin system is present in the endocrine 
cells of pancreatic islets and to assess its 
regulation by hypoxia and in a transplant 
setting. Our results provide the necessary 
biological basis for the study design of 
endothelin agonist/antagonist treatment before 
and/or after islet transplantation and its 
putative impact on graft viability and 
function. 
We were able to show the presence of ET-1, 
ETA- and ETB-receptors in endocrine cells of 
human and rat pancreata by immunohisto-
chemical staining. In human pancreatic beta-
cells, all three components of the endothelin 
system (ET-1, ETA- and ETB-receptor) can be 
detected whereas alpha cells were only 
positive for ET-1. Somatostatin-expressing 
delta-cells were negative for all three 
components which is in agreement with a 
Figure 9. Immunohistochemical staining of the endothelin system in rat islets before and after transplantation. The two 
left columns: pancreatic sections with insulin in green and the endothelin system in red. The two right columns: 
engrafted islets in liver sections with insulin in green and the endothelin system in red. Bar = 50 µm; same
magnification in all pictures. 
JOP. J Pancreas (Online) 2008; 9(2):133-149. 
JOP. Journal of the Pancreas - http://www.joplink.net - Vol. 9, No. 2 - March 2008. [ISSN 1590-8577] 145
previous study [28]. Interestingly, in contrast 
to human pancreatic islets, the alpha-cells of 
rat islets were also positive for ETB-receptors, 
weakly positive for ETA-receptors, and delta-
cells showed immunoreactivity for ET-1. 
Such species-specific differences in 
expression levels of the components of the 
endothelin system have been described 
elsewhere [29, 30]. Therefore, species-
dependent differences in the biological 
activities of the endothelin system need to be 
anticipated when drawing conclusions from 
animal experimentation for human biology. 
Preclinical experiments could involve 
transplanting human islets into non-obese 
diabetic severe combined immunodeficiency 
(NOD-SCID) mice which might provide a 
possible solution for the study of human islet 
biology in a transplant setting, but brings up 
the problems of xenotransplantation. As no 
perfect experimental model exists, biological 
findings need to be confirmed in human 
experimentation. 
Endothelin receptor expression on pancreatic 
islet cells was confirmed by binding studies 
with radiolabeled ligand and competition by 
unlabeled ET-1 or receptor-specific 
antagonists. The binding capacity for ET-1 is 
comparable to other tissues such as the liver 
or heart, both of which have also been shown 
to express ET-receptors on parenchymal cells 
[31, 32]. Both the relatively high ET-1 
binding capacity in islet tissue and the 
presence of ETA- and ETB-receptor mRNA in 
beta-cell lines (RINm5f, INS-1) strongly 
supports the immunohistochemical finding of 
non-endothelial expression of the two 
receptor subtypes in pancreatic islets. ETA- 
and ETB-receptors are expressed at a ratio of 
nearly 1:1 based on competition binding 
experiments with the specific antagonists 
BQ123 or BQ788, respectively. The presence 
of both receptor subtypes in isolated islets 
was confirmed by the ability of either of the 
antagonists to prevent ET-1-stimulated 
phosphorylation of p42/p44 MAP kinases, 
both of which are downstream mediators of 
endothelin signaling [33]. The finding of 
endothelin receptor expression on endocrine 
cells of pancreatic islets supports previous 
observations by which endothelin stimulates 
insulin secretion in isolated islets [34, 35]. It 
was suggested that stimulation of insulin 
secretion was mediated indirectly through the 
activation of glucagons-producing alpha-cells 
[21]. However, the evidence shown for ET-
receptor expression on beta-cells and the 
ability of endothelin to elicit a raise in 
intracellular Ca2+ suggests a direct 
insulinotropic effect of endothelin on 
pancreatic beta-cells [36, 37]. 
Endothelins do not only regulate vascular 
homeostasis [38], but also mediate cell 
proliferation [39, 40] and are involved in the 
promotion or prevention of apoptosis [17, 41]. 
Several biological properties of endothelin 
may therefore also have a direct impact on 
islet cell survival and function after 
intrahepatic transplantation. For example, in 
adipocytes or rat lung epithelial cells, ET-1 
reduces tumor necrosis factor-alpha (TNF-
alpha)-induced expression of inducible nitric 
oxide synthase (iNOS) [42, 43]. TNF-alpha in 
combination with other proinflammatory 
cytokines is released either through the 
activation of Kupffer cells or by islet resident 
macrophages known to promote beta-cell 
dysfunction and apoptotic beta-cell death via 
synthesis of nitric oxide [44, 45]. ET-1 
mediates cytoprotection through the inhibition 
of iNOS, which is especially relevant in tissue 
inflammation, considering the fact that 
proinflammatory cytokines stimulate the 
expression of this hormone [46, 47]. 
Another beneficial function of ET-1 could be 
the ability to stimulate angiogenesis through 
enhanced expression of the vascular 
endothelial growth factor (VEGF) [48, 49]. 
ET-1 stabilizes hypoxia-inducible factor-1-
alpha (HIF-1-alpha) which then promotes the 
transcription of the VEGF gene. Both factors, 
VEGF and HIF-1-alpha, are expressed in islet 
cells and could therefore not only stimulate 
islet revascularization but also provide 
cytoprotection from hypoxia-related graft 
injury [50, 51]. The majority of the above-
described biological activities of ET-1 will be 
potentially advantageous to islet survival and 
engraftment, especially in the post-
transplantation period where near-ischemia 
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may be prevalent in the islet graft [52, 53]. In 
vitro, hypoxia stimulates the expression of 
ET-1 and ETB-receptor mRNA whereas ETA- 
receptor steady state transcript levels are 
slightly reduced. This could be confirmed 
only partially in our syngeneic rat islet 
transplantation model where ETB-receptor 
staining intensity seemed to be increased 
while ETA-receptor and ET-1 immuno-
reactivity was strongly reduced. This 
discrepancy between in vitro and in vivo 
regarding the level of ET-1 expression may be 
explained by the more complex biology 
present in a transplantation setting. A very 
similar regulation pattern of the endothelin 
system was also found in a rat liver model of 
1 h ischemia followed by 6 h of reperfusion 
[54]. While, in the liver, the described 
specific regulation pattern of the endothelin 
system may warrant a balanced action of 
vasodilators and vasoconstrictors under 
ischemic conditions, its involvement in 
ischemic islets remains speculative. It is 
conceivable that, in transplanted islets, altered 
expression of the endothelin system reflects a 
biological response by which cytoprotection 
is promoted through upregulation of the ETB-
receptor and microcirculation is improved by 
downregulation of ET-1. 
In summary, our study clearly demonstrates 
the presence of ET-1 and its ETA and ETB 
receptors in non-endothelial, hormone-
producing cells of pancreatic islets. Its 
oxygen-dependent expression strongly 
suggests a rescue mechanism by which islet 
cells adapt to hypoxic conditions. These 
findings are of importance with respect to a 
potential therapeutic application of ET-1 
antagonists in islet transplantation as has been 
used successfully in other organ transplant 
models. Further investigation is needed to 
shed light on the question as to whether the 
potential benefits of antagonizing endothelin 
in clinical islet transplantation outweigh the 
potent angiogenic and cytoprotective effect of 
endothelin demonstrated in other tissues. 
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